NASDAQ NMS - GLOBAL MARKET · GTBP
+4.68% · +$0.0132 · Vol 253.3K
Market closed · last close 4:00 PM ET · price as of 19:24:37 ET
GT Biopharma Inc

GT Biopharma Inc

Biotechnology
$0.2952
Card
Relationship Map

Veridion Score

BETALOW CONF · 6/6 factorsMethodology
GTBP
GT Biopharma Inc
Fri Aug 21 · last completed session · Markets closed · resumes Mon 9:30 ET
AVOID

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

25/ 100
Veridion Score
AVOID · LOW confidence
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: LOW · 6/6 factors with data · Fri Aug 21 · last completed session · Markets closed · resumes Mon 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is GTBP moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading GTBP catalysts
About GT Biopharma Inc
PHARMACEUTICAL PREPARATIONS
Listed since
2021
Employees
1
Country
US

GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. The company is engaged in discovering, developing, and commercializing therapeutics from its proprietary product platform across various disease areas, mainly focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platform offers immuno-oncology products designed to treat hematologic malignancies, sarcoma, and solid tumors.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$0.2822
Day high
$0.2950
Day low
$0.2821
Previous close
$0.2820
52W high
$1.14
-74.11% from high
52W low
$0.2720
3% of range
Market cap
$13M
EPS
$-10.1100
Beta
2.49
Shares out
45.1M
Volume
253.3K
0.44× rel vol
Avg volume
573.3K
VWAP
$0.2899
Price history computed in-house
1W
-0.27%
1M
-8.97%
3M
-32.91%
1Y
-73.41%
YTD
-62.40%
SMA 50 $0.3773 · below
SMA 200 $0.4998 · below
52W position 3%

GTBP overview

Veridion Score
25
Registered · 2026-08-21
6 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around GTBP.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading GTBP Form 4 filings
Public disclosures

Congress activity in GTBP

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for GTBP in the cached public ledger.

Federal contracts

GTBP contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for GTBP in this window.
Lobbying spend

GTBP lobbying filings, year to date.

Registered lobbying filings matched to GT Biopharma Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for GTBP in this window.
Loading news for GTBP
Analyst ratings
Sovereign unlock shows live analyst consensus for GTBP.
Options
Sovereign unlock shows live options positioning for GTBP.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.